1. Home
  2. ATNM vs SER Comparison

ATNM vs SER Comparison

Compare ATNM & SER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Actinium Pharmaceuticals Inc. (Delaware)

ATNM

Actinium Pharmaceuticals Inc. (Delaware)

HOLD

Current Price

$1.52

Market Cap

47.1M

Sector

Health Care

ML Signal

HOLD

Logo Serina Therapeutics Inc.

SER

Serina Therapeutics Inc.

HOLD

Current Price

$2.92

Market Cap

42.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ATNM
SER
Founded
2000
2017
Country
United States
United States
Employees
31
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
47.1M
42.0M
IPO Year
N/A
2018

Fundamental Metrics

Financial Performance
Metric
ATNM
SER
Price
$1.52
$2.92
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
2
Target Price
$4.00
$13.00
AVG Volume (30 Days)
224.5K
15.1K
Earning Date
11-14-2025
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$90,000.00
$116,000.00
Revenue This Year
N/A
$134.46
Revenue Next Year
$42,943.57
N/A
P/E Ratio
N/A
N/A
Revenue Growth
11.11
N/A
52 Week Low
$1.03
$3.12
52 Week High
$2.41
$7.92

Technical Indicators

Market Signals
Indicator
ATNM
SER
Relative Strength Index (RSI) 57.56 26.45
Support Level $1.37 $3.15
Resistance Level $1.69 $4.26
Average True Range (ATR) 0.09 0.23
MACD 0.02 -0.03
Stochastic Oscillator 52.78 1.47

Price Performance

Historical Comparison
ATNM
SER

About ATNM Actinium Pharmaceuticals Inc. (Delaware)

Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications, and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.

About SER Serina Therapeutics Inc.

Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers. The Company has one reportable segment relating to the research and development of its POZ platform.

Share on Social Networks: